Abnormal phosphatase 2A for the treatment of (PP2A) and the diagnosis of Alzheimer's disease

摘要

The present invention relates to a method of screening a compound for the treatment or prevention of Alzheimer's disease and methods for diagnosing Alzheimer's disease. These methods are based on the fact that the newly discovered differences in events related molecules and protein phosphatase 2A functions in cells of Alzheimer's disease when compared to control cells (PP2A). In one embodiment, it is compared to control the difference in basal PP2A gene expression in cells of Alzheimer's disease. In another aspect, I compared in control cells and test cells, the differences in enzyme activity and protein PP2A. In another embodiment, I compare the difference in response to a substance which inhibits the function of PP2A. In cells of Alzheimer's disease and normal cells, another aspect is to detect differences in (subcellular) distribution of intracellular phosphorylated Erk1 / 2 which is a substrate of PP2A further. By detecting the differences specific to Alzheimer's disease events and related functions of PP2A in peripheral tissues, the basis of diagnostic test kits and valid test very practical for the early diagnosis of Alzheimer's disease is provided, biochemical basis for identifying therapeutic targets for drug development is provided.